Pharmacotherapy of Methamphetamine Addiction: An Update
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Methamphetamine dependence is a serious public health problem worldwide for which there are no approved pharmacological treatments. Psychotherapy is still the mainstay of treatment; however, relapse rates are high. The search for effective pharmacological treatment has intensified in the last decade. This review will highlight progress in pharmacological interventions to treat methamphetamine dependence as well as explore new pharmacological targets. Published data from clinical trials for stimulant addiction were searched using PubMed and summarized, as well as highlights from a recent symposium on methamphetamine pharmacotherapy presented at the ISAM 2006 meeting, including interim analysis data from an ongoing D-amphetamine study in Australia. Early pilot data are encouraging for administering D-amphetamine and methylphenidate as treatment for heavy amphetamine users. Abilify at 15 mg/day dose increased amphetamine use in an outpatient pilot study. Sertraline, ondansetron, baclofen, tyrosine, and imipramine were ineffective in proof-of-concept studies. Development of pharmacotherapy for methamphetamine dependence is still in an early stage. Data suggesting D-amphetamine and methylphenidate as effective pharmacotherapy for methamphetamine addiction will need to be confirmed by larger trials. Preclinical data suggest that use of GVG, CB1 antagonist, and lobeline are also promising therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A role for lateral hypothalamic orexin neurons in reward seeking
Harris, G. C., Wimmer, M., & Aston-Jones, G. (2005) · Nature · doi:10.1038/nature04071 · Cited by 1,311 · cited 1×
“Other pharmacological targets for stimulants addiction, for which a rationale is in earlier stages of development, include Orexin-A receptor antagonists (72,73), Opioid receptor-like 1”
BackgroundVolkow, N. D., Chang, L., Wang, G.-J., Fowler, J. S., Ding, Y.-S., Sedler, M., Logan, J., Franceschi, D., Gatley, J., Hitzemann, R., et al. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.12.2015 · Cited by 916 · cited 1×
“Positron emission tomography (PET) imaging studies have shown decreased dopamine D2 receptors in chronic MA users, which correlate with cognitive impairment (4).”
BackgroundUnmanageable motivation in addiction: a pathology in prefrontal-accumbens glutamate transmission
Kalivas, P. W., Volkow, N., & Seamans, J. (2005) · Neuron · doi:10.1016/j.neuron.2005.02.005 · Cited by 657
Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior
Boutrel, B., Kenny, P. J., Specio, S. E., Martin-Fardon, R., Markou, A., Koob, G. F., & de Lecea, L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507480102 · Cited by 520
Shaham, Y., Erb, S., Leung, S., Buczek, Y., & Stewart, J. (1998) · Psychopharmacology · doi:10.1007/s002130050608 · Cited by 302
Dopamine D3Receptor Antagonism Inhibits Cocaine-Seeking and Cocaine-Enhanced Brain Reward in Rats
Vorel, S. R., Ashby, C. R., Paul, M., Liu, X., Hayes, R., Hagan, J. J., Middlemiss, D. N., Stemp, G., & Gardner, E. L. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-21-09595.2002 · Cited by 269
Ciccocioppo, R., Economidou, D., Fedeli, A., & Massi, M. (2003) · Physiology & Behavior · doi:10.1016/s0031-9384(03)00112-4 · Cited by 74
Johnson, B. A., Roache, J. D., Ait-Daoud, N., Wallace, C., Wells, L. T., & Wang, Y. (2005) · Psychopharmacology · doi:10.1007/s00213-004-1998-0 · Cited by 33
Cited by
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
“Substitute prescribing with dexamphetamine or methylphenidate for treatment of amphetamine dependence has been reported as possibly beneficial in small studies (Elkashef et al., 2008) (IV).”
BackgroundEffects of Length of Abstinence on Decision-Making and Craving in Methamphetamine Abusers
Wang, G., Shi, J., Chen, N., Xu, L., Li, J., Li, P., Sun, Y., & Lu, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068791 · Cited by 261
Pharmacological approaches to methamphetamine dependence: a focused review
Karila, L., Weinstein, A., Aubin, H., Benyamina, A., Reynaud, M., & Batki, S. L. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03639.x · Cited by 242
Amphetamine-group substances and HIV
Colfax, G., Santos, G.-M., Chu, P., Vittinghoff, E., Pluddemann, A., Kumar, S., & Hart, C. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60753-2 · Cited by 167
Caprioli, D., Venniro, M., Zeric, T., Li, X., Adhikary, S., Madangopal, R., Marchant, N. J., Lucantonio, F., Schoenbaum, G., Bossert, J. M., et al. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.02.018 · Cited by 145
Metadata
- Authors
- Elkashef, A., Vocci, F., Hanson, G., White, J., Wickes, W., & Tiihonen, J.
- Venue
- Substance Abuse
- Publisher
- SAGE Publications
- Published
- 2008-08
- Volume
- 29
- Issue
- 3
- Pages
- 31-49
- ISSN
- 0889-7077 (ISSN-L)
- 1547-0164
- OpenAlex
- W2023643911
- Cited by
- 120
- References
- 8
- FWCI
- 7.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacotherapy of Methamphetamine Addiction: An Update. https://app.cochat.ai/papers/10.1080/08897070802218554
- The paper
- Elkashef, A., Vocci, F., Hanson, G., White, J., Wickes, W., & Tiihonen, J. (2008). Pharmacotherapy of Methamphetamine Addiction: An Update. Substance Abuse. https://doi.org/10.1080/08897070802218554
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.